Mesothelioma Cancer Centers
Rutgers Cancer Institute of New Jersey
Doctors Affiliated with this Treatment Facility
Rutgers Health offers mesothelioma cancer treatment through their Rutgers Cancer Institute of New Jersey. Rutgers uses a patient-centered approach, using a multidisciplinary team to develop a treatment plan that is specific to the patient’s wants and needs. For specialized care, Rutgers offers a Mesothelioma Treatment and Research Program.
Mesothelioma patients that attend Rutgers Cancer Institute receive care from surgical oncologists, medical oncologists and radiation oncologists, allowing them to undergo surgery, chemotherapy, radiation and other cancer treatments. Rutgers also offers clinical trials to eligible mesothelioma patients with the latest experimental treatments.
Within the Rutgers team of specialists resides Dr. H. Richard Alexander, Jr. He serves on the Board of Directors for the Mesothelioma Applied Research Foundation, allowing him to bring the latest mesothelioma news to the Rutgers treatment program. The research aspect of the mesothelioma program at Rutgers allows patients to have access to the latest diagnostic tools and treatment techniques.
Patients also have access to various support services at the Cancer Institute of New Jersey to help with their treatment and survivorship journey. Social work, cancer exercise groups, education programs and a cancer transitions group allows patients to maintain comfort and a high quality of life.
- HIPEC treatment
- Mesothelioma clinical trials
- Peritoneal mesothelioma
- Pleural mesothelioma
- BIG Cancer Research Consortium member
- National Cancer Institute Comprehensive Cancer Center designation
- ScreenNJ Cancer Prevention Education and Detection partner
Mesothelioma Clinical Trials at Rutgers Cancer Institute of New Jersey
The following clinical trials are in progress or actively recruiting participants at Rutgers Cancer Institute of New Jersey:
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Conditions: Advanced Malignancies Last Updated: April 26, 2019 Status: Active, not recruiting
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma; Pleural Mesothelioma Last Updated: July 5, 2018 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
Rutgers Cancer Institute of New Jersey. Mesothelioma Treatment and Research Program.
Rutgers Cancer Institute of New Jersey. Mesothelioma Research and Treatment Physician Team.